[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Central Finland Hospital District\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":100},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100299028","prosthesis-versus-osteosynthesis-in-proximal-tibia-fractures-100299028",false,"NCT03172715","Prosthesis Versus Osteosynthesis in Proximal Tibia Fractures","Prosthesis Versus Osteosynthesis in Treatment of Intra-articular Fractures of Proximal Tibia: A Randomized, Controlled, Trial","POSITIF","Inclusion Criteria:\n\n* Acute intra-articular proximal tibia fracture with impression of the joint cartilage (Schatzker grades II to VI)\n* Impression of tibial plateau min 2 mm\n* Intact patellar tendon\n* The patient accepts both treatment options (osteosynthesis and arthroplasty)\n\nExclusion Criteria:\n\n* Not voluntary\n* Previous arthroplasty of the knee\n* Previous fracture affecting the knee joint\n* Inability to co-operate\n* Not independent (institutionalized living before fracture)\n* Severe osteoarthritis (Kellgren-Lawrence grade 4)\n* Open fracture (Gustilo grade 2 or over)\n* Progressive metastatic malign disease\n* Multiple fractures requiring operative treatment\n* Severe soft tissue injury around the knee (Tscherne classification grade 3)\n* Avulsion fracture of the patellar tendon or concomitant patellar tendon tear\n* Inability to walk before fracture\n* Severe medical comorbidities\n* Body Mass Index over 40\n* Unacceptably high risk of surgery due to severe medical comorbidities\n* Significant arterial or nerve trauma\n* Severe substance abuse","ALL","65 Years",{"count":20,"type":21},98,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of this study is to compare knee function and pain one year after treatment of intra-articular proximal tibia fracture using either osteosynthesis with a locking plate (ORIF) or primary total knee replacement (TKR) in patients over 65 years of age.",[27],"Tibial Fractures",[29,30,31,32],"Open reduction internal fixation","Arthroplasty","Surgery","Randomized controlled trial","RECRUITING","2024-08-21",{"date":36,"type":37},"2024-08-22","ACTUAL",{"date":39,"type":37},"2018-01-09",{"date":41,"type":21},"2029-06",{"name":43,"class":44},"Central Finland Hospital District","OTHER",8,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100536955","phase-2-transdermal-estradiol-and-exercise-in-mitigating-adverse-effects-of-androgen-deprivation-therapy-for-prostate-cancer-radiation-therapy-100536955","NCT06271551","Transdermal Estradiol and Exercise in Mitigating Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer Radiation Therapy","Transdermal Estradiol and Exercise in Mitigating Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer Radiation Therapy: A Randomized Controlled Trial","ESTRACISE","Inclusion Criteria:\n\n* Men with localized prostate cancer, and scheduled for external beam radiation with adjuvant subcutaneous androgen deprivation therapy, leuprorelin (LHRH agonist) for at least 12 months without any other endocrinology treatments for prostate cancer\n* Adults (age over 18 years)\n* Sufficient performance status (Eastern Cooperative Oncology Group, 0-1)\n* Body mass index between 18.5 - 30.0\n* Willingness to participate and signed consent\n\nExclusion Criteria:\n\n* Patients with low-risk prostate cancer (ISUP Gleason grade 1)\n* Patients with expected adjuvant androgen deprivation therapy for less than one year\n* Distant bone, lymph node, or soft tissue metastasis\n* Cardiac pacemaker\n* Prior recent cardiovascular event or stroke (\\\u003C12 months)\n* Past or current venous thromboembolism\n* Other untreated or unstable malignancy in risk of recurrence\u002Fprogression (as judged by the treating physician)\n* Concurrent glucocorticoid treatment\n* Physical disabilities for regular exercise\n* Any medication or condition considered as a contraindication to estradiol (allergy to adjuvant compounds (carbomer, trolamine), history with thromboembolic disorders (protein C, protein S, or antithrombin deficiency), porphyria, acute or previous liver disease, drugs with cytochrome P450 enzyme metabolism (anticonvulsants: phenobarbital, phenytoin, carbamazepine; anti-infectives: rifampicin, rifapentine, nevirapine, efavirenz; and St. John's wort)) or leuprorelin (allergy to adjuvant compounds (polylactic acid), Qt-time prolonging drugs (quinidine, disopyramide, amiodarone, sotalol, dofetilide, ibutilide, methadone, moxifloxacin, antipsychotics)\n* Known allergy to estradiol or leuprorelin\n* Expected poor compliance or expected survival time of less than one year","MALE","18 Years",{"count":57,"type":21},310,[59],"PHASE2","The goal of the clinical trial is to find out whether transdermal estradiol will reduce the adverse effects of androgen deprivation therapy in prostate cancer patients.\n\nThe primary aim of this study is to estimate the efficacy of transdermal estradiol (E2) in reducing androgen deprivation therapy induced adverse effects on sexual function. A secondary aim of this study is to estimate the utility of E2 and the combination of E2 with supervised exercise in reducing other androgen deprivation therapy related adverse effects.\n\nParticipants (n=310) will use transdermal estradiol for 12 months concomitant to androgen deprivation therapy. The use of transdermal estradiol will start at the beginning of the trial, at the same time as androgen deprivation therapy. A subgroup of participants (n=120) will also be allocated to perform six months supervised resistance training.\n\nResearchers will compare transdermal estradiol group to control group, and resistance training groups and non-training control groups.",[62],"Prostate Cancer",[64,65],"Prostate cancer","Androgen deprivation therapy","NOT_YET_RECRUITING","2024-02-20",{"date":69,"type":37},"2024-02-21",{"date":71,"type":21},"2024-03",{"date":73,"type":21},"2029-12",{"name":43,"class":44},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},"100416771","urinary-retention-after-arthroplasty-100416771","NCT04707001","Urinary Retention After Arthroplasty","Urinary Retention After Arthroplasty - UREA Trial","UREA","Inclusion Criteria:\n\n* elective total knee arthroplasty\n\nExclusion Criteria:\n\n* previous surgery for urologic cancer\n* fracture as indication for surgery\n* lack of co-operation\n* untreated urinary retention\n* nephrostoma\n* general anesthesia",true,{"count":85,"type":21},170,[24],"Arthroplasty increases the risk of postoperative urinary retention. Treatment of postoperative urinary retention is indwelling or intermittent catheterization. The need for catheterization is most commonly determined with an ultrasound scanner. Catheterization increases the risk of urinary tract infection, which may further lead to haematogenic infection of the artificial joint. There is no evidence of an optimal way to monitor the onset of spontaneous urination.\n\nThe aim of the study is to determine whether monitoring the onset of spontaneous urination after fast track knee arthroplasty is safe based on symptoms alone without ultrasound monitoring.",[89,90],"Urinary Retention Postoperative","Arthroplasty Complications","2024-02-12",{"date":93,"type":37},"2024-02-13",{"date":95,"type":37},"2021-05-01",{"date":97,"type":21},"2026-07",{"name":43,"class":44},1,""]